newsfilter
← Latest News
GlobeNewswire·

Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights

- Multiple Phase 2 readouts for EDP1815 in atopic dermatitis expected in 2023; data from first three cohorts expected in early 1Q 2023 and fourth cohort in 2Q 2023 - - Phase 2 data for first extracellular vesicle